Asthma and lower airway disease
Therapeutic efficacy of omalizumab

https://doi.org/10.1016/j.jaci.2008.10.053Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (25)

  • Repositioning of anti-cancer drug candidate, AZD7762, to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn

    2018, Biochemical Pharmacology
    Citation Excerpt :

    Although these drugs have immediate effects in a variety of allergic diseases, antihistamines cause drug resistance due to repeated administration, and corticosteroids can cause side effects by inducing hormone changes in the body [36]. Omalizumab, an anti-IgE drug that interferes with the binding of FcεRI and IgE in mast cells, has an excellent efficacy but has a disadvantage in that it is expensive to patients [37]. Therefore, we are studying drugs that target signaling molecules that are involved in the activation of IgE-mediated mast cells.

  • Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

    2016, Journal of Allergy and Clinical Immunology
    Citation Excerpt :

    For individual patients, it is unlikely that reductions in levels of biomarkers, such as free serum IgE or blood cell FcεRI alone, will be sufficient to predict responses to anti-IgE treatment.34 There are many other factors involved, including cellular IgE receptor expression (FcεRI and FcεRII/CD23), specific/total IgE ratios, and cellular sensitivity,35 even before considering local tissue IgE concentrations and permeation of the drug to the tissue site. In conclusion, QGE031 was well tolerated in adults with mild allergic asthma.

  • Cytomegalic hepatitis in a patient receiving omalizumab

    2016, IDCases
    Citation Excerpt :

    That way, it prevents the activation of these cells and the consequent liberation of pro-inflammatory mediators [11–14]. On the other hand, it also causes a gradual reduction of FceRI receptor expression, desensitizing cells to stimulation by allergen [15–17]. Regarded as a relatively safe drug, phase III trials have demonstrated a very low incidence of adverse effects [18,19].

  • Anti-Immunoglobulin E Therapy

    2014, Middleton's Allergy: Principles and Practice: Eighth Edition
  • Monitoring free serum IgE in severe asthma patients treated with omalizumab

    2012, Respiratory Medicine
    Citation Excerpt :

    Nevertheless, a long-term trial to test the clinical potential of monitoring free serum IgE in omalizumab patients is warranted. This further trial is important since in vitro results demonstrate down-regulation of FcɛRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE.29 It is tempting to speculate that long-term treatment with anti-IgE may decrease the doses of omalizumab necessary to uphold a sufficient treatment response.

View all citing articles on Scopus

Disclosure of potential conflict of interest: D. MacGlashan receives grant support from the National Institutes of Health.

View full text